Axcella Therapeutics (AXLA)

Interim Analysis Shows Signs of Early Efficacy


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
September 30, 2022
Report ID: 25254
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Axcella Therapeutics
Axcella Therapeutics
Healthcare
Biotechnology
Ticker
AXLA
Current Price
$0.6586 -1.7%
Market Cap
$24.0M
Price Target
Refer to Report
Volume
207.2K
52wk Range
$0.1621 - $2.89

Comments

0
No comments yet...
Related Research Reports
1/25/2023

Long COVID Phase 2b/3 Trial Changes The AXA1125 Outlook
Long COVID Phase 2b/3 Trial Changes The AXA1125 Outlook (AXLA)
12/16/2022

Down But Not Out After Restructuring
Down But Not Out After Restructuring (AXLA)
11/2/2022

3Q22 Reported After An Eventful Quarter
3Q22 Reported After An Eventful Quarter (AXLA)
9/30/2022

Interim Analysis Shows Signs of Early Efficacy
Interim Analysis Shows Signs of Early Efficacy (AXLA)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2023 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.